Moderna’s new COVID-19 vaccine mNexspike approved by FDA, but there’s a limit on who can use it

The U.S. has approved Moderna’s new COVID-19 vaccine, mNexspike, which is a lower-dose option targeting high-risk individuals aged 65 and older, and those aged 12 to 64 with health conditions, reflecting a more cautious approach to vaccine distribution. This decision contrasts with the unrestricted availability of Moderna’s existing vaccine, which is approved for individuals six months and older. The FDA’s approval was based on studies showing mNexspike’s safety and effectiveness, occurring amid changes in CDC recommendations under Health Secretary Robert F. Kennedy Jr. questioning the benefits of COVID-19 vaccines for healthy children.

Full Article